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Abstract
Background: Outcome reporting bias (ORB) occurs when variables are selected for publication based on their
results. This can impact upon the results of a meta-analysis, biasing the pooled treatment effect estimate.
The aim of this paper is to show how to assess a systematic review and corresponding trial reports for ORB using
an example review of intravenous and nebulised magnesium in the treatment of asthma.
Methods: The review was assessed for ORB by 1) checking the reasons, when available, for excluding studies to
ensure that no studies were excluded because they did not report the outcomes of interest in the review; 2)
assessing the eligible studies as to whether the review outcomes of interest were reported. Each study was
classified using a system developed in the ORBIT (Outcome Reporting Bias In Trials) project to indicate whether
ORB was suspected and a reason for the suspicion. Authors of trials that did not report the outcomes of interest
were contacted for information. A sensitivity analysis was performed to assess the robustness of the conclusions of
the review to this potential source of bias.
Results: Twenty-four studies were included in the review; two studies had been excluded for not reporting either
of the two outcomes of interest. Six included studies did not report hospital admission and two did not report
pulmonary function. There was high suspicion of outcome reporting bias in four studies. Results from the
sensitivity analysis indicate that review conclusions were not overturned.
Conclusion: This paper demonstrates, with the example of the magnesium review, how to assess a review for
outcome reporting bias. A review should not exclude studies if they have not reported the outcomes of interest
and should consider the potential for outcome reporting bias in all included studies.
Background
Over the past decade, evidence-based medicine and evi-
dence-based health policy have become dominant
themes in clinical and health services research [1].
A systematic review is a method used to review research
literature and summarise evidence from multiple studies
that fit pre-specified eligibility criteria in order to answer
a specific research question [2]. Systematic reviews are
important as they can identify areas where the evidence
that is available is insufficient and new trials are
required [3].
Empirical research in randomised controlled trials
(RCTs) provides strong evidence of an association
between studies that report positive or significant results
(P < 0.05) and publication; with studies that report posi-
tive or significant results being more likely to be pub-
lished [4]. Such bias, termed study publication bias, is
well recognised as a potential threat to the validity of
any meta-analysis and can make the readily available
evidence unreliable for decision making [5,6].
Outcome reporting bias (ORB) has been defined as
the selection on the basis of the results of a subset of
the original outcomes recorded for inclusion in publica-
tion of trials [7]. Up until recently ORB has received
less attention than study publication bias. A recent
review of empirical research provides strong evidence
that outcomes that are statistically significant have
higher odds of being fully reported (range of odds ratios:
2.2 to 4.7) [4]. Sensitivity analyses have been suggested * Correspondence: kerry.dwan@liverpool.ac.uk
1Centre for Medical Statistics and Health Evaluation, University of Liverpool,
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analysis to ORB [6,8].
Cochrane reviews now include an assessment of the
risk of bias within each included study [9]. There are six
included domains: sequence generation; allocation con-
cealment; blinding; incomplete outcome data; selective
outcome reporting and other sources of bias. For ‘selec-
tive outcome reporting,’ the reviewers must state how
the possibility of selective outcome reporting was exam-
ined and what was found.
The prevalence and impact of outcome reporting bias
in an unselected cohort of systematic reviews has
recently been described [10] (Appendix 1). It was found
that a third of Cochrane reviews contained at least one
trial with high ORB suspicion for the review primary
outcome. Within this work, a nine point classification
system was developed to assess the risk of ORB within
trial reports.
The aim of this paper is to illustrate how to assess a
systematic review for ORB, how to classify suspicion of
ORB within the trials using the nine point classification
system and how to undertake a sensitivity analysis to
assess the robustness of the conclusions of a meta-
analysis to this potential source of bias along with study
publication bias.
Steps to consider in examining potential for ORB
Assessing a review
The first step when assessing a review for ORB is to
check the reasons for excluding studies to ensure that
no studies were excluded because they did not report
the outcomes of interest in the review (Appendix 2). If a
trial report does not give results for, or mention certain
outcomes this does not necessarily mean that they were
not measured or analysed. Cochrane reviews routinely
provide a list of excluded studies with reasons for their
exclusion. When the review is not a Cochrane review
and this information is not provided within the publica-
tion it may be necessary to contact the review authors.
The second step is to check the studies that were
included in the review as to whether they report none,
one or all outcomes the reviewers are interested in.
The third step is to obtain the trial reports of those
studies that were listed in the review (or through con-
tact with the reviewer if a list was not available) as
excluded because they did not report on any of the out-
comes of interest and the eligible studies which did not
report on one or more of the outcomes of interest.
Using the trial reports a matrix is constructed, with the
outcomes of interest in the review and those reported in
the trial reports listed in columns and the different stu-
dies listed in the rows (Table 1). The reason other trial
outcomes are looked at is that in some cases outcomes
may be structurally related so that if one outcome was
reported, it is known that the other must have been
measured. For example, if length of hospital stay had
been reported then hospital admission must have been
noted. Also, some outcomes are often measured routi-
nely together so that if one outcome is reported but not
the other this may raise suspicions that selective report-
ing has occurred e.g. systolic and diastolic blood
pressure.
Trial assessment using the classifications
For eligible studies not reporting the outcomes of inter-
est, it is important to assess the likelihood that the out-
comes had been measured and selectively not reported.
The fourth step is to complete the matrix constructed
in step three by applying the ORBIT nine point classifi-
cation system.
Each study is given a classification (see Table 2) along
with a reason, using verbatim trial report text whenever
appropriate to support the chosen classification. The
classification is determined by comparing the methods
to the results section of the trial report, by looking at
which other outcomes were measured and reported and
accounting for knowledge of the clinical area. This
should be completed by at least two people indepen-
dently and differences should be discussed to agree on
an overall classification to determine whether there is a
high or low risk of outcome reporting bias.
Contacting authors
After the matrix has been completed in step four, step
five involves an attempt to contact the trialists from the
trials included in the review that did not report the out-
comes of interest. The purpose of this contact is to clar-
ify whether the chosen classification is correct and when
possible to obtain data to include in an updated meta-
analysis. However, in the process of conducting a
review, it could be argued that this step should be taken
straight after identifying studies not reporting the out-
come of interest.
Sensitivity analysis for assessing the impact of
ORB
The purpose of the sensitivity analysis in step six is to
determine whether the conclusions of the meta-analysis
are robust to the assumption that selective reporting has
occurred. A method proposed to consider the potential
effect of study publication bias has been adapted for
ORB [8] and may be used to simultaneously consider
robustness to both ORB and study publication bias. The
formula used in this sensitivity analysis is provided as a
worked example in appendix 3. The sensitivity analysis
provides a treatment effect estimate and confidence
interval which should be compared against the original
results to consider the robustness of that result.
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Page 2 of 10Table 1 Outcome matrix
Trial ID Review primary
outcomes
Trial outcomes
Pulmonary
function
Hospital
admission
Blood
pressure
Severity
score
Respiratory
score
Calcium/
potassium/
magnesium
Respiratory
frequency or
rate
Hospital stay/
length of
hospital stay
Heart
rate
Side
effects
Other outcomes
Dadhich, 2003
[17]
✘✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ○ Bronchodilating effects
Santana, 2001
[18] (children)
✘✘ ○ ✘✘ ✔ ✔ ✔ ✔ ✔ arterial blood gasses, oxygen therapy, ph,
nebulisations, acidosis
Bijani, 2002 [22]
(adults)
✔✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ Number of breathing, diaphoresis, cyanosis,
Using respiratory access muscles, clinical
asthma score
Bessmertny,
2002 [21]
(adults)
✔✘ ○ ✘✘ ○○ ✘ ○ ✔ oxygen saturation
Gurkan, 1999
[24] (children)
✔✘ ○ ✘✘ ✘ ✘ ✘ ○○Nebulisations, clinical asthma score
Devi, 1997 [23]
(children)
✔✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✔ Clinical asthma score, oxygen saturation,
pulsus paradoxus
Tiffany, 1993
[26] (adults)
✔✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘
Meral, 1996
[25] (children)
✔✘ ○ ✘✔ ✘ ○ ✘ ○ ✔✘
Boonyavorakul,
2000 [19]
(adults)
✘✔ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘
Scarfone, 2000
[20] (children)
✘✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ Pulmonary index score, oxygen saturation
✔ indicates full reporting of results for treatment comparison of interest
✘ indicates no reporting
○ indicates partial reporting (i.e. only the p-value is given for the comparison)
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0The method is applied when the number of eligible stu-
dies not reporting the outcome of interest is known,
additional information obtained from trialists may also
be utilised. For example the trialists may confirm that the
outcome was not measured eliminating that study from
suspicion of ORB. The sensitivity analysis can also be cal-
culated for an additional number of unpublished or
unobserved studies to see how many would be required
to overturn the conclusions of the meta-analysis. Then
plausibility of this number can then be considered.
Reviewers may wish to obtain statistical advice regard-
ing application of the proposed sensitivity analysis and
the interpretation of the results. However, this sensitivity
analysis can be conducted in excel and an excel file can
be obtained from the first author on request.
Example
The systematic review ‘Intravenous and nebulised mag-
nesium sulphate for acute asthma’ [11] was assessed.
Interest in this review arose as three of the co-authors
(RKD, CP and PRW) are involved in the HTA-funded
MAGnesium NEbuliser Treatment In Children (MAG-
NETIC) study (HTA 05/503/10, http://www.hta.ac.uk/
1615). This review is clinically important as asthma
affects 5.2 million people in the UK, including 1.1
million children [12], and is responsible for around 63
000 hospital admissions per year [13]. Magnesium sul-
phate has been suggested as an alternative treatment
option in patients resistant to standard asthma therapy
[11], either in intravenous or nebulised dosage form.
Pulmonary function tests (PFTs) and hospital admis-
sion are clinically relevant to acute asthma [14], and con-
sequently are the primary outcomes of the review. Peak
expiratory flow rate (PEFR) and forced expiratory volume
in one second (FEV1) are common pulmonary function
tests [15]. This review includes both adults and children
however it is difficult to obtain PEFR measurements
in children with acute asthma, so trials involving children
may not have measured this outcome [16]. Meta-analyses
were conducted in this review, subgrouped by trials with
adults and children, for studies using intravenous and
nebulised magnesium compared with placebo (Table 3).
Results from the ORB assessment
Review assessment
The review inclusion criteria stated that trials that
reported a measure of pulmonary function or hospital
admission as an outcome were eligible. There were 24
studies included in the review. Of these, 22 studies
reported on pulmonary function and 18 studies reported
on hospital admission.
The review stated that two studies [17,18] were
excluded: one study [18] because it did not report either
of these outcome measures and the other [17] because
it was only available in abstract form and the authors
could not be contacted.
Therefore in total there were four studies [17-20] that
did not report pulmonary function and eight studies
that did not report hospital admission [17,18,21-26].
Since both outcomes are important clinical outcomes in
Table 2 The ORBIT classification system for missing or incomplete outcome reporting [10]
Classification Description Level of
reporting
Level of suspicion of
ORB
Clear that the outcome was measured and analysed
A States outcome analysed but only reported that result not significant
(typically stating p-value > 0.05).
Partial High risk
B States outcome analysed but only reported that result significant (typically stating
p-value < 0.05).
Partial Low risk
C States outcome analysed but insufficient data presented to be included in
meta-analysis or to be considered to be fully tabulated.
Partial Low risk
D States outcome analysed but no results reported. None High risk
Clear that the outcome was measured
E Clear that outcome was measured but not necessarily analysed. None High risk
F Clear that outcome was measured but not necessarily analysed. None Low risk
Unclear that the outcome was measured
G Not mentioned but clinical judgment says likely to have been measured and
analysed.
None High risk
H Not mentioned but clinical judgment says unlikely to have been measured. None Low risk
Clear that the outcome was NOT measured
I Clear that outcome was not measured. N/A No risk
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review due to selective reporting should be considered.
Trial assessment and classifications
The outcome matrix (Table 1) shows which outcomes
were reported for each trial differentiating between
those which were fully reported or partially reported, i.e.
effect size or precision only reported along with sample
size or a p-value [27]. This helps in the assessment of
ORB in some cases, for example it can be seen that
length of hospital stay was fully reported for one study
and yet hospital admission was not reported [18] raising
suspicions that ORB may have occurred in this trial.
Four of the authors [KD, RKD, CP, SM - two clini-
cians and two statisticians] gave a classification indepen-
dently to each eligible study that did not report hospital
admission or pulmonary function. The individual and
overall classifications with reasons are given in Addi-
tional file 1. The differences were discussed between the
four authors and an overall classification agreed. Con-
sensus was easily reached for the majority of study clas-
sifications. However, for the abstract by Dadhich et al.
[17] it was more difficult to agree on an overall classifi-
cation for pulmonary function due to the information
reported.
Information obtained from trialists
Lead authors were contacted first by email and if no
reply was received, then by post. If no contact details
could be located or no reply was received, co authors
were contacted. There was an attempt to contact all
trialists of the studies that did not report on the review
Table 3 Results of meta-analyses and sensitivity analyses
Outcome Review results Number of
studies
suspected of
ORB
Number of participants
missing from the meta-
analysis (%)
Sensitivity analysis results
ORB alone Study
publication
bias *
Intravenous Magnesium: children
Hospital
admission
RR 0.69 (95% CI 0.53, 0.90) from
3 studies, I
2 = 17.7%, RE.
Favours intervention
3 [18,23,24] 117 (50%) RR 0.76 (95% CI: 0.58, 0.99) for one study
as trialists confirmed that for the other
two it was not measured.
1
Pulmonary
function
SMD 1.94 (95% CI: 0.80, 3.08)
from 4 studies, I
2 = 84.4%, RE.
Favours intervention
2 [18,20] 104 (45%) NA: both studies given H classifications
and this was confirmed by trialists
4
Intravenous Magnesium: adults
Hospital
admission
RR 0.87 (95% CI 0.70, 1.08) from
8 studies, I
2- = 30%, RE. Favours
intervention
2 [22,26] 129 (14%) NA: confirmed by trialists that this was
not measured
4
Pulmonary
function
SMD 0.25 (95% CI -0.01, 0.51)
from 9 studies, I
2 = 70.6%, RE.
Favours intervention
1 [19] 33 (3%) NA: results from one study obtained and
included in an updated meta-analysis
Updated SMD 0.24, (95% CI 0,
0.48) from 10 studies, RE.
I
2 = 67%
7
Nebulised Magnesium: children
Hospital
admission
RR 2 (95% CI 0.19, 20.93) from 1
study, RE. Favours control
1 [25] 40 (39%) NA: confirmed by the trialists that this
was not measured
1
Pulmonary
function
SMD -0.26 (95% CI -1.49, 0.98)
from 2 studies, I
2 = 88.9%, RE.
Favours control
0 0 NA: all eligible studies reported on this
outcome
1
Nebulised Magnesium: adults
Hospital
admission
RR 0.68 (95% CI 0.46, 1.02) from
6 studies, I
2 = 0, RE. Favours
intervention
1 [21] 74 (17%) RR 0.76 (95% CI 0.51, 1.13) 8
Pulmonary
function
SMD 0.17 (95% CI -0.02, 0.36) 7
studies, I squared 1.2%, RE.
Favours intervention
0 0 NA: all eligible studies reported on this
outcome
5
*: number of unpublished studies required to overturn review conclusions after allowing for ORB. When the result is statistically significant this implies the result
becoming non-significant. When the result is not statistically significant, the reported value is the number required to change the direction of treatment effect.
NA: Not Applicable; RE: random effects
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nine out of the ten trialists [18-26], either lead or co
authors. Additional file 1 shows the responses received
and it is assumed the information given by trialists
regarding whether or not the outcome was measured
is correct.
Pulmonary function
Four studies did not report pulmonary function. Contact
with the authors confirmed that two of the studies
[18,20] not reporting pulmonary function did not mea-
sure it. The authors of one study [19] sent the summary
data for this outcome and the p-value indicated that it
was not statistically significant. Our assessment of the
classifications of ORB were correct in these three cases
(75%). There was no reply from one author [17]. With-
out additional information for this study we are unable
to confirm whether the classification is correct however
the suspicion of ORB remains high.
Hospital admission
Eight studies did not report hospital admission. There
was no reply from one author [17]. For three studies
[18,22,25] all patients were hospitalised over the study
period hence the outcome was not applicable due to the
study design but this was not clear in the trial report.
One study [23] reported length of hospital stay. Their
correspondence suggests they reported hospital admis-
sion as ER admits, however, the study inclusion criteria
requires admission to ER. Further clarification was
sought but not provided. One of the remaining three
studies [21] not reporting hospital admission did mea-
sure this outcome but found no difference between the
groups. Two studies did not measure hospital admission
[24,26]. Our assessment was therefore correct in only
one of these eight cases [21] which was mainly due to
the outcome, hospital admission being harder to define
compared to pulmonary function.
Results of the Sensitivity analysis for assessing
the impact of ORB
The results of the sensitivity analysis are provided in Table
3. Although there was a high level of suspicion of ORB for
the study by Dadhich et al. [17] it is not included in the
sensitivity analysis; although the abstract states that they
used nebulised magnesium it does not state whether the
trial was conducted in children or adults. Therefore it is
not known which meta-analysis it would have been
included in had relevant results been reported.
Intravenous magnesium sulphate
For intravenous magnesium sulphate compared with
placebo, the review concluded that “it is an effective
treatment in children, being associated with a significant
improvement in pulmonary function and a 30% decrease
in hospital admissions.” However, they found “weak evi-
dence that intravenous magnesium sulphate improves
pulmonary function in adults, but no evidence of a sig-
nificant effect upon hospital admissions, although the
data do not exclude a potential reduction in admissions
of up to 30%.”
The sensitivity analysis indicated that the conclusions
of the review would not be overturned (i.e. when the
result is statistically significant, the conclusions would
be overturned if the result becomes non-significant.
When the result is not statistically significant, the con-
clusions would be overturned if the direction of treat-
ment effect changed). However, for hospital admission
in children, after allowing for the study suspected of
ORB it was estimated that the results may not be robust
if one further unpublished study was identified (Appen-
dix 3 and Figure 1). As results were supplied for one
study, the meta-analysis for pulmonary function in
adults was updated (Table 3).
Nebulised magnesium sulphate
For nebulised magnesium sulphate, the review con-
cluded that “insufficient data exist to draw reliable con-
clusions regarding the role of nebulised magnesium
sulphate in children” but found “weak evidence that
nebulised magnesium sulphate improves pulmonary
function and reduces hospital admissions in adults.” The
results of the sensitivity analysis indicated that the con-
clusions of the review would not be overturned, chan-
ging the direction of the treatment effect (Table 3).
Figure 1 Plot of the treatment effect estimate using the bound
for maximum bias sensitivity analysis for hospital admission
for children.
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Systematic reviewers should routinely assess the poten-
tial impact of ORB. Cochrane systematic reviewers are
now recommended to undertake an assessment of this
risk of bias. This tutorial demonstrates how to apply a
recently developed nine point classification system to
the trials included in a systematic review to assess ORB
and when a meta-analysis is conducted, how to conduct
a sensitivity analysis to consider the robustness of
results to both ORB and study publication bias. Examin-
ing the existence and potential impact of these biases
will increase the validity of inferences concerning
healthcare interventions.
Strengths and limitations of the study
The authors who conducted the review ‘Intravenous and
nebulised magnesium sulphate for acute asthma’ did
request unpublished data from the trialists by email
with little success. This was due to both difficulties in
locating trialists and their co authors since many trials
were quite old, and a lack of response. There has been
more success during this work in contacting trialists,
through searching for more recent published work by
authors to obtain up to date contact details, by contact-
ing colleagues of authors and attempting to contact all
co authors on the published papers.
A limitation of this work is that while Cochrane
reviews include a list of excluded studies together with
reasons for exclusion, the vast majority of reviews,
which are non-Cochrane reviews (80%) [28] often do
n o t .I far e v i e wd o e sn o ts t a t ea n ys t u d i e sa se x c l u d e d ,
the review authors should be contacted to ask if any stu-
dies were excluded and the reasons for exclusion. If it
proves impossible to obtain this information, a thorough
assessment of ORB cannot be completed until the
review is updated and the search strategy re run.
There was a large amount of heterogeneity between
studies, possibly due to the different measures used to
assess pulmonary function (e.g. FER and PEFR). Hetero-
geneity needs to be investigated through meta-regres-
sion, sub group analysis, or ideally an individual patient
data meta-analysis. The values of I s q u a r e d[ 2 9 ]s h o w n
in Table 3 (70.6%, 84.4%, 88.9%) raise the question as to
whether a meta-analysis should have been conducted.
However, even when there is a large amount of hetero-
geneity, it may be preferable to quantitatively synthesise
the data rather than a qualitative interpretation of the
results, as long as the limitations of the methods are
properly acknowledged [30].
Classifications G and H are subjective and therefore it
is recommended that this assessment should be com-
pleted by two experienced reviewers independently and
differences discussed. Further data on interrater
variation is required, to investigate how much this
depends on the review context and the degree of clinical
experience. Statisticians are used to thinking about the
potential for bias so it may be helpful to include them
in this process. It may be easier to predict classifications
for some outcomes compared to others. In the example
used in this paper, pulmonary function was easier to
predict as it is a measure used in clinical practice whilst
hospital admission is used more for research and was
more difficult to predict. Health care provision and facil-
ities vary in different countries. Hospital admission is
likely to have been measured in most studies but some
may not have wanted to use it as an outcome measure
since it is open to many more confounding factors,
compared with pulmonary function tests (PFTs). Hospi-
tal admission is a weak surrogate for response to treat-
ment, since numerous other considerations enter into
the decision to admit: treating physician bias, type of
insurance (e.g USA), home environment and ability to
obtain medication plus known or suspected compliance
[31]. Further examples of the different classifications
are shown in Table 1 of the supplementary material in
the main ORBIT paper [10].
The sensitivity analysis is computationally simple and
therefore quick to compute and can be estimated for
any type of outcome. Work has been undertaken to
show the accuracy of the classification system [10] and
the robustness of this method of sensitivity analysis [8].
Conclusions and policy implications for systematic
reviews
These methods are useful for those conducting systematic
reviews and explains the steps in assessing a review for
ORB. Trials with missing outcome data should be scruti-
nised by reviewers, and a trialist contacted if a study does
not report results for the outcomes of interest. The lack of
reporting of specified outcome(s) should not be an auto-
matic reason for exclusion of studies. Methods that have
been developed to assess the robustness of the conclusions
of systematic reviews to ORB should be applied.
A balance needs to be considered between the use of
resources and the quality of a review. For example, if
results from several studies are missing, (whether the
results are pooled or discussed narratively) the review
may be of high risk of bias and incorrect conclusions
regarding treatment may be made. This is especially
important to consider when there is a large proportion
of participants in eligible studies which have not been
included in the meta-analysis compared to those that
are included in the meta-analysis [32]. Another impor-
tant aspect to consider is when the outcome of interest
is one that would be expected to be commonly collected
by most investigations of a particular intervention.
Dwan et al. Trials 2010, 11:52
http://www.trialsjournal.com/content/11/1/52
Page 7 of 10Approximately half of all reviews do not report a
meta-analysis [28]. It is important to know how to
assess ORB when there is no meta-analysis. During the
work on a review, data is extracted for each paper and
whether or not a meta-analysis is conducted, each out-
come is summarised. Therefore, it should be possible to
tell which studies do not report the outcomes of interest
and still apply the nine point classification system and
assess the risk of bias.
Trialists are sometimes contacted during the review
process for other information regarding study design
and therefore it is suggested that trialists should also be
asked about outcomes. It has been shown that it is pos-
sible to contact authors for older trials and obtain infor-
mation and even data, if one persists. This should be
encouraged in order to maximise the validity of a
review. We found that a Google search often led to
more recent contact details.
This work is important in raising awareness of the
problem of outcome reporting bias and the importance
of assessing ORB within a review and corresponding
trial reports. Clinical trials registers and the advance
publication of detailed protocols with an explicit
description of outcomes and analysis plans should help
combat these problems, along with the development of
core outcomes for specific clinical areas [33]. Legiti-
mate changes to outcomes stated in the protocol, pro-
tocol amendments, and the statistical analysis
plans should be described by trialists in the manu-
script. Trialists should be encouraged to write up and
submit for publication without selection of results,
especially with the increased use of online journals
where more space is available.
Future research
There are other outcomes which are important in
asthma, such as intubation and the need for ICU,
intravenous therapy and an asthma severity score
(there are over 15). These outcomes are measured and
reported in a variable way. It has been suggested that
the development of a set of universally agreed out-
comes for a condition could improve the quality of
trials and help reduce the selective reporting of out-
comes [33,34]. Therefore the development of a set of
core outcomes and measurement scales for asthma is
crucial.
In the meantime, this work provides guidance to those
conducting systematic reviews and by following the
steps described here, the risk of outcome reporting bias
within a review can be assessed and its potential impact
on the results and conclusions discussed.
Appendix
Appendix 1: Summary of the ORBIT study
The ORBIT study examined the prevalence of outcome
reporting bias in RCTs and its impact on a large, unse-
lected cohort of Cochrane reviews.
A nine point classification system for missing outcome
data in randomised trials was developed and applied to
the trials within these Cochrane reviews.
Outcome reporting bias was suspected in at least one
trial in more than a third of reviews.
In a sensitivity analysis, nearly a fifth of statistically
significant meta-analyses of the review primary out-
come would have become non-significant after adjust-
ing for outcome reporting bias and a quarter would
have overestimated the treatment effect by 20% or
more.
Outcome reporting bias is an under-recognised pro-
blem that affects the conclusions in a substantial pro-
portion of Cochrane reviews.
Appendix 2: How to assess a review for outcome
reporting bias
Step 1: Check the reasons why studies were excluded
from the review to ensure no eligible studies are
excluded only because they do not report the outcome
of interest. If this information is not available, contact
the review authors for information.
Step 2: Check to see if any of the included studies do
not report on the outcomes of interest.
Step 3: Obtain the trial reports for those studies that
do not report the outcome of interest or were excluded
for not reporting the outcomes of interest. Construct an
outcome matrix to indicate which review outcomes
were reported in the trial reports, along with other trial
outcomes.
Step 4: Decide on a classification (Table 2) for each
study that does not report the outcome of interest and
give a reason for the chosen classification to indicate
your level of suspicion of ORB.
Step 5: Contact trial authors to find out if they did
measure the outcome of interest (the truth) and try to
obtain the data (aggregate results or individual patient
data) to include in an update of the review. If data are
unavailable, ask why they did not report the outcome of
interest.
However, when conducting a review, step 5 should be
attempted before step 4.
Step 6: Conduct a sensitivity analysis to assess the
robustness of the conclusions of the review after taking
into account the trialists response for studies where it
is suspected outcome reporting bias has occurred i.e.
Dwan et al. Trials 2010, 11:52
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unless in the case of a G classification it is thought
that the outcome was probably not reported because
there were no events. The sensitivity analysis can also
be extended to assess the effect of unpublished studies
that are not known about due to study publication
bias.
Appendix 3: Sensitivity analysis example
Intravenous magnesium, children - Hospital admission
The bias bound is obtained by calculating the bias b and
then adding (or subtracting) this value to the pooled
treatment effect estimate on a symmetric scale to move
it closer to the null.
b
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To calculate the bound (b), values are needed for n
(the number of trials included in the meta-analysis), m
(the number of studies in which there is a high suspi-
cion of ORB plus a range of values for the potential
number of unpublished trials), si(the standard errors of
the trials included in the meta-analysis) and τ
2(the
between study variance). In this case, n =3a n dm =1
(for ORB) and 2 to 10 (for example, for study publica-
tion bias) after taking into account information from tri-
alists (Additional file 1). The values for si and τ
2 are
shown in Additional file 2.
The values are then inserted into equation for b, when
m=1 .
b
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.
The value b is added to the original pooled treatment
effect estimate (Figure 1) to move the result towards the
null. For this outcome, the estimate used was the rela-
tive risk (RR). Therefore, the value of b is added to the
log of the pooled relative risk. The same is also done for
the lower and upper bound of the confidence intervals.
Adjusted estimate Exp Ln pooled RR b
Exp Ln 69 ..
= () + ⎡ ⎣ ⎤ ⎦
= () + 00 0 9 98
Exp 273
76
⎡ ⎣ ⎤ ⎦
=− []
=
0
0
.
.
The adjusted estimate (RR 0.76 (95% CI 0.58, 0.99))
is less favourable towards magnesium sulphate than
the original meta-analysis however the result is still
statistically significant. This implies that the conclusion
of the review for the effect of intravenous magnesium
on hospital admission in children appears to be robust
to ORB. The red lines in Figure 1 indicate that it
w o u l dt a k er e s u l t sf r o mo n ef u r t h e rs t u d yt ob em i s s -
ing (either the outcome not being reported in a pub-
lished study or the whole study being unpublished) to
change the results from being statistically significant to
non-significant (i.e. for the upper confidence interval
to cross one indicating no significant difference).
Figure 1 shows how the adjusted pooled estimate and
confidence intervals change as the number of missing
studies increases.
Additional file 1: Classifications comparison table.
Additional file 2: Hospital admission: data for included studies.
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